Want to see AU:ARX full AI Analyst Report?
ARX Stock Chart & Stats
AU$0.56
AU$0.02(3.57%)
At close: 4:00 PM EDT
AU$0.56
AU$0.02(3.57%)
Day’s Range― - ―
52-Week RangeAU$0.50 - AU$0.80
Previous CloseN/A
Volume338.11K
Average Volume (3M)302.12K
Market Cap
AU$197.16M
Enterprise ValueAU$196.49
Total Cash (Recent Filing)AU$22.60M
Total Debt (Recent Filing)AU$5.31M
Price to Earnings (P/E)31.3
Beta0.61
Next Earnings
Nov 26, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.02
Shares Outstanding345,902,650
10 Day Avg. Volume330,836
30 Day Avg. Volume302,123
Financial Highlights & Ratios
PEG Ratio-0.23
Price to Book (P/B)2.48
Price to Sales (P/S)2.23
P/FCF Ratio24.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$1.08Price Target Upside92.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.01
Revenue Forecast (FY)AU$120.57M
Bulls Say, Bears Say
Bulls Say
Sustained Multi‑year Revenue GrowthConsistent revenue growth from A$20.5m to A$92.3m over several years shows durable commercial adoption of the ovine ECM platform. Sustained top‑line momentum supports scale economics, continued investment in channels and R&D, and reduces execution risk over the next several quarters.
Conservative Balance Sheet / Low LeverageVery low debt relative to equity provides financial flexibility and a capital cushion to fund growth, clinical development, and commercialization. Conservative leverage reduces refinancing risk and supports durable investment capacity across 2–6 months and beyond.
Improved Cash Generation And Profitability InflectionThe shift to positive operating and free cash flow alongside a move to profitable EBIT and net income reflects higher quality earnings and cash conversion. This improvement lowers dependence on external funding and supports durable reinvestment in sales, manufacturing, and clinical activities.
Bears Say
Historical Earnings And Cash‑flow VolatilityWide swings from multi‑year losses to recent profitability show earnings and cash generation are not yet proven across a business cycle. This volatility implies execution and adoption risk: sustained positive conversion must be demonstrated to be considered durable.
Modest Net Margins And Limited Margin Track RecordDespite high gross margins, net margin remains modest and profitability has only recently recovered. Limited history of consistent net profitability raises risk that operating leverage, SG&A or reimbursement shifts could compress margins, challenging durable earnings growth.
Dependence On Distribution And Private‑label ChannelsHeavy reliance on distributors and private‑label/OEM relationships can limit pricing control, margin capture, and direct customer feedback. Structural dependence on partners can slow brand recognition and creates channel concentration risk that may constrain durable margin and adoption gains.
Aroa Biosurgery Ltd News
ARX FAQ
What was Aroa Biosurgery Ltd’s price range in the past 12 months?
Aroa Biosurgery Ltd lowest share price was AU$0.49 and its highest was AU$0.80 in the past 12 months.
What is Aroa Biosurgery Ltd’s market cap?
Aroa Biosurgery Ltd’s market cap is AU$197.16M.
When is Aroa Biosurgery Ltd’s upcoming earnings report date?
Aroa Biosurgery Ltd’s upcoming earnings report date is Nov 26, 2026 which is in 115 days.
How were Aroa Biosurgery Ltd’s earnings last quarter?
Aroa Biosurgery Ltd released its earnings results on May 25, 2026. The company reported AU$0.017 earnings per share for the quarter, beating the consensus estimate of AU$0.004 by AU$0.013.
Is Aroa Biosurgery Ltd overvalued?
According to Wall Street analysts Aroa Biosurgery Ltd’s price is currently Undervalued.
Does Aroa Biosurgery Ltd pay dividends?
Aroa Biosurgery Ltd does not currently pay dividends.
What is Aroa Biosurgery Ltd’s EPS estimate?
Aroa Biosurgery Ltd’s EPS estimate is 0.
How many shares outstanding does Aroa Biosurgery Ltd have?
Aroa Biosurgery Ltd has 345,902,650 shares outstanding.
What happened to Aroa Biosurgery Ltd’s price movement after its last earnings report?
Aroa Biosurgery Ltd reported an EPS of AU$0.017 in its last earnings report, beating expectations of AU$0.004. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Aroa Biosurgery Ltd?
Currently, no hedge funds are holding shares in AU:ARX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aroa Biosurgery Ltd Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
AU$1.08 (92.26% Upside)
AU$1.08 (92.26% Upside)
Blogger Sentiment
Bullish
AU:ARX Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth AU$125.8K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.50%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
1.55%
Trailing 12-Months
Company Description
Aroa Biosurgery Ltd
Aroa Biosurgery Limited operates as a regenerative medicine company dedicated to the development, production, and global distribution of medical solutions for wound and tissue repair. The firm innovatively utilizes extracellular matrix (ECM) technology, with its market presence spanning the United States and international territories. Its product line encompasses Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold, tailored for managing both acute and chronic wounds. Additionally, the company offers Myriad Matrix, an engineered ECM device designed for soft tissue repair, reinforcement, and complex wound treatment, along with Myriad Morcells, a powdered version of Myriad Matrix serving similar soft tissue and complex wound applications. Rounding out its offerings are Reinforced Bioscaffolds, a specialized surgical product employed in ventral hernia repair and abdominal wall reconstruction. Founded in 2007, Aroa Biosurgery Limited is headquartered in Auckland, New Zealand.
ARX Stock 12 Month Forecast
Average Price Target
AU$1.08
▲(92.26% Upside)
Technical Analysis
Polynovo
―
Cochlear
―
Impedimed Limited
―
OncoSil Medical Ltd
―
EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
―








